Claris Lifesciences was up 4.2% at Rs 255.90 at 15:09 IST on BSE after the bulk deals data on BSE yesterday, 27 July 2016, showed that two foreign funds mopped up some of the shares of the company which were offloaded by a promoter group firm.
Meanwhile, the S&P BSE Sensex, was up 209.16 points or 0.75% at 28,233.49
On BSE, so far 3.72 lakh shares were traded in the counter, compared with an average daily volume of 2.15 lakh shares in the past one quarter. The stock hit a high of Rs 258.95 and low of Rs 247.50 so far during the trading session. The stock had hit 52-week high of Rs 270 on 26 July 2016. The stock had hit 52-week low of Rs 126.10 on 12 February 2016. The stock had outperformed the market over the past one month till 27 July 2016, gaining 16.94% compared with 6.14% rise in the Sensex. The scrip had also outperformed the market in past one quarter, surging 57.14% as against the Sensex's 7.52% rise.
The small cap company has equity capital of Rs 54.57 crore. Face value per share is Rs 10.
As per the bulk deals data on BSE yesterday, 27 July 2016, foreign fund East Bridge Capital Master Fund bought 24.20 lakh shares of Claris Lifesciences at an average price of Rs 210 per share. Another foreign fund Morgan Stanley Asia Singapore Pte bought 7.83 lakh shares at an average price of Rs 210 per share. In the same bulk deal, promoter group firm Abellon Energy offloaded 46 lakh shares at an average price of Rs 211.66 per share. Abellon Energy was holding 59.28 lakh shares of the company constituting at 10.86% stake as on 30 June 2016, as per the company's shareholding pattern available with the stock exchanges. The total holding of promoters in the company stood at 60.99% as on 30 June 2016. The Claris Lifesciences stock had lost 0.46% to settle at Rs 245.45 on BSE yesterday, 27 July 2016, when the bulk deal was executed.
Claris Lifesciences' consolidated net profit fell 65.8% to Rs 3.57 crore on 7.77% rise in net sales to Rs 166.76 crore in the quarter ended 31 March 2016 over the quarter ended 31 March 2015.
Also Read
Claris Lifesciences is the holding company of Claris Injectables. Claris Injectables is a wholly-owned subsidiary of Claris Injectables dealing in specialty injectables business. Claris Lifesciences is also the holding company of Claris Otsuka Private Limited, a joint venture with Japan's Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. for Infusion business in India and emerging markets.
Powered by Capital Market - Live News